Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration

뉴스 본문을 불러오고 있어요.

Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration | 웨이프 WAPE

Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration

기사 요약

관련 종목

댓글 —